Substance P (SP) is a neuropeptide belonging to the family of tachykinins. It acts in the central nervous system (CNS) as a neurotransmitter, neuromodulator, and neurotrophic factor binding the G-protein-coupled receptor NK1, which is the tachykinins receptors' form predominant in the brain. The expression of SP is particularly high in nervous structures critically involved in pathogenesis of Parkinson's disease (PD), including the enteric nervous system, the vagus nerve, the autonomic centers, the neocortex and the limbic areas, and, especially, the substantia nigra. In theory, the levels of SP might reflect neurodegeneration in these systems, thus representing a potential, ideal biomarker for PD. However, although many studies explored the dynamics of SP modulation in PD animal models, data from patients are still not available.
Serum substance P is increased in Parkinson's disease and correlates with motor impairment / Schirinzi, T.; Maftei, D.; Ralli, M.; Greco, A.; Mercuri, N. B.; Lattanzi, R.; Severini, C.. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - 37:1(2022), pp. 228-230. [10.1002/mds.28824]
Serum substance P is increased in Parkinson's disease and correlates with motor impairment
Maftei D.Secondo
;Ralli M.;Greco A.;Lattanzi R.Penultimo
;
2022
Abstract
Substance P (SP) is a neuropeptide belonging to the family of tachykinins. It acts in the central nervous system (CNS) as a neurotransmitter, neuromodulator, and neurotrophic factor binding the G-protein-coupled receptor NK1, which is the tachykinins receptors' form predominant in the brain. The expression of SP is particularly high in nervous structures critically involved in pathogenesis of Parkinson's disease (PD), including the enteric nervous system, the vagus nerve, the autonomic centers, the neocortex and the limbic areas, and, especially, the substantia nigra. In theory, the levels of SP might reflect neurodegeneration in these systems, thus representing a potential, ideal biomarker for PD. However, although many studies explored the dynamics of SP modulation in PD animal models, data from patients are still not available.File | Dimensione | Formato | |
---|---|---|---|
Schirinzi_Serum substance_2022.pdf
solo gestori archivio
Note: Schirinzi_Serum substance_2022
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
219.54 kB
Formato
Adobe PDF
|
219.54 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.